Michael R. Bishop to Recurrence
This is a "connection" page, showing publications Michael R. Bishop has written about Recurrence.
Connection Strength
0.492
-
Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion. Chin Med J (Engl). 2013 Nov; 126(22):4380-8.
Score: 0.095
-
Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S62-73.
Score: 0.083
-
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54.
Score: 0.078
-
Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol. 2000 Jun; 18(11):2269-72.
Score: 0.037
-
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000 Apr; 25(7):717-22.
Score: 0.037
-
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017; 5:11.
Score: 0.030
-
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
Score: 0.028
-
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012 Nov 15; 120(20):4256-62.
Score: 0.022
-
Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S94-100.
Score: 0.019
-
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503.
Score: 0.019
-
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Cytotherapy. 2003; 5(6):542-52.
Score: 0.011
-
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002; 8(4):213-20.
Score: 0.010
-
Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 01; 92(5):1832-6.
Score: 0.008
-
High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol. 1998 Sep; 9(9):1023-6.
Score: 0.008
-
Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. Exp Hematol. 1995 Dec; 23(14):1503-8.
Score: 0.007